The TLPLDC vaccine is made by ex vivo priming matured autologous dendritic cells with yeast cell wall particles (YCWPs) loaded with tumor lysate, particle only (TLPO) vaccine . Patients receiving the TLPO vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment), this was not randomized . Safety was assessed and Kaplan-Meier and log-rank analyses compared disease-free (DFS) and overall survival (OS)